Developing Novel Therapies from Neonatal Cardiac Progenitor Cells (nCPCs)
nCPC: The Ideal Stem Cell for Clinical Development
Manufacturing Consistency
Adult stem cells exhibit significant variability from person to person, making it difficult to achieve the consistency required by the U.S. FDA for drug development. Our lead drug, STM-01, and its secretome, STM-21, are derived from neonatal sources (babies under 30 days old), ensuring near-zero variability. This breakthrough eliminates a key challenge in producing reliable, scalable stem cell-based therapies.
Maximal Potency
The regenerative potential of stem cells decreases with age—cells from older donors are less potent than those from younger donors. This is why we heal quickly when we’re young, and more slowly as we age. In head-to-head studies published in peer-reviewed journals, our lead nCPC, STM-01, has proven significantly more potent than any adult-derived stem cell.
Scale and Cost of Goods
Exponentially more nCPCs can be produced from a single donor compared to adult cells, driving down production costs and minimizing the number of donors needed.
Non-Fetal Source
While embryonic or fetal stem cells also possess minimal inter-donor variability, their use is complicated by ethical and political considerations. Cells sourced from neonates avoid these issues while maintaining their potency and manufacturing advantages.
Learn More About Our Ongoing Clinical Studies
EXPANDED ACCESS POLICY
Secretome Therapeutics is committed to developing promising new therapies to address the unmet medical needs of patients suffering from rare and serious diseases with unmet need.
We currently have an early-stage investigational medicine in our product pipeline for the treatment of heart failure with preserved ejection fraction, and for dilated cardiomyopathy. Our goal is to provide access to our medicine at the appropriate time and in a manner that is most beneficial to the relevant patient populations. We believe enrollment in our ongoing clinical trials is the safest and most effective way of achieving this goal.
We do recognize that some patients will not be eligible for our clinical trials and may wish to access our products through expanded access. However, at this time, we do not have the resources available to offer expanded access use of our investigational medicine.
We encourage all patients and physicians who are interested in accessing our investigational medicine to visit clinicaltrials.gov to find out about enrolling.
Secretome Therapeutics may revise this expanded access policy at any time. Additionally, the posting of this policy by Secretome Therapeutics does not serve as a guarantee of access to any specific investigational new drug by any individual patient.
If you have any questions, please reach out to us at [email protected]. You can find further contact details on the Contact Information section of our website.
Please check back periodically for updates on EAP clinical trials.
Contact Information
Baltimore Office
323 W. Camden Street, Suite 600
Baltimore, MD 21201
Chicago Lab
400 N. Aberdeen Street, Suite 900
Chicago, IL 60642
Plano Office
7250 Dallas Parkway, Suite 400
Plano, TX 75024